Hope for resistant hypertension through BrigHTN and PRECISION

R M Touyz¹, D G Harrison^{2

3

4

5}

Affiliations

¹ Research Institute of the McGill University Health Centre (RI-MUHC), Department of Medicine and Department of Family Medicine, McGill University, Montreal, Quebec, Canada. Rhian.touyz@mcgill.ca.
² Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Department of Physiology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁵ Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.

Comment

R M Touyz et al. Nat Rev Nephrol. 2023 Apr.

. 2023 Apr;19(4):216-217.

doi: 10.1038/s41581-023-00676-2.

R M Touyz¹, D G Harrison^{2

3

4

5}

¹ Research Institute of the McGill University Health Centre (RI-MUHC), Department of Medicine and Department of Family Medicine, McGill University, Montreal, Quebec, Canada. Rhian.touyz@mcgill.ca.
² Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Department of Physiology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁵ Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.

No abstract available

Comment on

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Freeman MW, et al. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7. N Engl J Med. 2023. PMID: 36342143 Clinical Trial.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.

1. Chobanian, A. V. Shattuck Lecture. The hypertension paradox — more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361, 878–887 (2009). - DOI - PubMed
1. Carey, R. M. et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 72, e53–e90 (2018). - DOI - PubMed
1. Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2213169 (2022). - DOI - PubMed
1. Schlaich, M. P. et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400, 1927–1937 (2022). - DOI - PubMed
1. Acelajado, M. C., Hughes, Z. H., Oparil, S. & Calhoun, D. A. Treatment of resistant and refractory hypertension. Circ. Res. 124, 1061–1070 (2019). - DOI - PubMed - PMC